Cite
HARVARD Citation
Thiery-Vuillemin, A. et al. (2022). Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. Lancet oncology. 23 (3), pp. 393-405. [Online].